French Regulatory Authority Gives Green Signal To Phio Pharma's Melanoma Trial

The French National Agency for the Safety of Medicines and Health Products has signed off Phio Pharmaceuticals Corp's PHIO clinical trial with its lead product candidate, PH-762 in melanoma.

• The Company expects to dose the first patient in Q1 of 2022.
•  PH-762 activates immune cells to recognize better and kill cancer cells. It reduces the expression of PD-1, a clinically validated target for immunotherapy. 
• Related: Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation.
• PD-1 is expressed by T cells and prevents them from killing other cells, including cancer cells. Therefore, reducing PD-1 expression can reduce the ability of cancer cells to evade T cell detection and killing.
• The Company's first clinical trial with PH-762 will be a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma. 
• The study features a dose escalation of PH-762 monotherapy.
• Price Action: PHIO shares are trading 12.60% higher at $1.07 during the market session on the last check Tuesday.